Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta

NCT01713231 | Completed Phase 4 DMC

• 1 other identifier: A02-M14-12A
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

• Overall Objective: To test the hypothesis that oral vitamin D supplementation at higher than currently prescribed doses has a beneficial effect on the skeleton of young patients with osteogenesis imperfecta (OI).
• Specific Aims: 1. To determine whether 12 months of high-dose vitamin D supplementation, compared to standard-dose vitamin D supplementation, increases areal bone mineral density z-scores at the lumbar spine. 2. To examine the effectiveness of high-dose vitamin D supplementation to increase trabecular and cortical bone mineral density at the radius. 3. To examine whether high-dose vitamin D supplementation has an effect on physiological determinants of bone mass (parathyroid hormone, activity of bone metabolism, muscle function).
• Background: In a preliminary cross-sectional study of 282 OI patients we observed an inverse relationship between serum 25-hydroxyvitamin D and parathyroid hormone levels and a positive relationship between circulating levels of 25-hydroxyvitamin D and lumbar spine areal bone mineral density z-scores. This suggested that high-dose vitamin D supplementation would have a beneficial effect on bone density. Most OI patients currently receive oral vitamin D supplementation of 400 International Units per day, but doses of 2000 International Units per day are safe and have been shown to be beneficial in studies on healthy adolescents.
• Study Design: This is a parallel-group double-blind randomized controlled trial of 12 months duration on 60 children and adolescents aged 6 to 19 years with a clinical diagnosis of OI. One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group'). The other group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group'). Randomization will be stratified according to pubertal status and bisphosphonate treatment status.
• Clinical Relevance: The proposed study aims at direct improvements in the care of OI patients. If a simple and low-cost 'intervention' such as high-dose vitamin D supplementation can be shown to be effective in relieving some of the disease burden associated with OI, the benefit to OI patients worldwide would be substantial.

Conditions

Osteogenesis Imperfecta

Keywords

osteogenesis imperfecta; high-dose vitamin D; bone density; muscle function

Outcome Measures

Primary Outcomes (1)

• Change in areal bone mineral density z-score of the lumbar spine

  LS-aBMD z-score will be used as the primary outcome.The lumbar spine is the standard site of measurement both in the clinical follow up of OI patients .

  at baseline and 12 months

Secondary Outcomes (1)

• Change in trabecular and cortical volumetric bone mineral density z-scores at the radius, as measured by pQCT, relative to baseline.

  at baseline and at 12 months

Other Outcomes (1)

• Percentage change in lower extremity muscle power per body weight, as measured by jumping mechanography, relative to baseline.

  baseline and 12 months

Study Arms (2)

standard-dose vitamin D

ACTIVE COMPARATOR

one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').

Dietary Supplement: standard-dose vitamin D (400IU per day)

high-dose vitamin D

EXPERIMENTAL

One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').

Dietary Supplement: high-dose vitamin D (2000 IU per day)

Interventions

standard-dose vitamin D (400IU per day) DIETARY_SUPPLEMENT

standard-dose vitamin D

high-dose vitamin D (2000 IU per day) DIETARY_SUPPLEMENT

high-dose vitamin D

Eligibility Criteria

• Age: 6 Years - 19 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Clinical diagnosis of OI of any type.

You may not qualify if:

• Any condition that renders bone density measurements at the lumbar spine impossible. An example for this is prior spinal fusion surgery.
• Bisphosphonate therapy for less than two years duration.
• Use of medication, other than bisphosphonates, known to affect bone metabolism or 25OHD serum concentrations. Examples are anti-epileptics, active vitamin D metabolites, corticosteroids and thyroid hormones.
• Liver and renal disease known to interfere with vitamin D metabolism.
• Any other disorder of calcium and phosphate metabolism (apart from vitamin D deficiency) that might interfere with PTH.

Sponsors & Collaborators

• Louis-Nicolas Veilleux Ph.D.: lead

Study Sites (1)

Shriners Hospitals for Children-Canada

Montreal, Quebec, H3G1A6, Canada

Location

Related Publications (1)

• Plante L, Veilleux LN, Glorieux FH, Weiler H, Rauch F. Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial. Bone. 2016 May;86:36-42. doi: 10.1016/j.bone.2016.02.013. Epub 2016 Feb 24.

  PMID: 26924265 DERIVED

MeSH Terms

Conditions

Osteogenesis Imperfecta

Interventions

Vitamin D

Condition Hierarchy (Ancestors)

Osteochondrodysplasias; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Collagen Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Secosteroids; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: postdoctoral fellow

Study Record Dates

• First Submitted: October 21, 2012
• First Posted: October 24, 2012
• Study Start: September 1, 2012
• Primary Completion: March 1, 2013
• Study Completion: July 1, 2014
• Last Updated: September 9, 2014

Record last verified: 2014-09

Locations

CA (1)